- Home
- RDI vs ANTX Comparison
RDI vs ANTX Comparison
Compare RDI & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDI
- ANTX
- Stock Information
- Founded
- RDI 1937
- ANTX 2017
- Country
- RDI United States
- ANTX United States
- Employees
- RDI N/A
- ANTX N/A
- Industry
- RDI Movies/Entertainment
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- RDI Consumer Discretionary
- ANTX Health Care
- Exchange
- RDI Nasdaq
- ANTX Nasdaq
- Market Cap
- RDI 32.3M
- ANTX 37.6M
- IPO Year
- RDI N/A
- ANTX 2022
- Fundamental
- Price
- RDI $1.43
- ANTX $1.26
- Analyst Decision
- RDI Hold
- ANTX Hold
- Analyst Count
- RDI 1
- ANTX 5
- Target Price
- RDI $2.40
- ANTX $3.50
- AVG Volume (30 Days)
- RDI 157.9K
- ANTX 133.1K
- Earning Date
- RDI 11-14-2024
- ANTX 11-13-2024
- Dividend Yield
- RDI N/A
- ANTX N/A
- EPS Growth
- RDI N/A
- ANTX N/A
- EPS
- RDI N/A
- ANTX N/A
- Revenue
- RDI $197,270,000.00
- ANTX N/A
- Revenue This Year
- RDI N/A
- ANTX N/A
- Revenue Next Year
- RDI $14.40
- ANTX N/A
- P/E Ratio
- RDI N/A
- ANTX N/A
- Revenue Growth
- RDI N/A
- ANTX N/A
- 52 Week Low
- RDI $1.22
- ANTX $0.87
- 52 Week High
- RDI $2.07
- ANTX $21.40
- Technical
- Relative Strength Index (RSI)
- RDI 51.96
- ANTX 43.51
- Support Level
- RDI $1.38
- ANTX $1.34
- Resistance Level
- RDI $1.50
- ANTX $1.28
- Average True Range (ATR)
- RDI 0.09
- ANTX 0.06
- MACD
- RDI 0.01
- ANTX -0.01
- Stochastic Oscillator
- RDI 71.43
- ANTX 18.18
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.